OBJECTIVE: To ascertain the microbiological consequences of WHO's recommendation for presumptive co-trimoxazole prophylaxis for infants with perinatal HIV exposure. METHODS: Using a longitudinal cohort design, we followed HIV-exposed and HIV-unexposed infants trimonthly for up to 18 months per infant. HIV-exposed infants received daily co-trimoxazole prophylaxis from 6 weeks to > or = 12 months of age. Using Streptococcus pneumoniae as our sentinel pathogen, we measured how co-trimoxazole altered nasopharyngeal colonization, pneumococcal resistance to antibiotics and serotype distribution as a function of co-trimoxazole exposure. FINDINGS: From 260 infants followed for 3096 patient-months, we detected pneumococci in 360/1394 (25.8%) samples. HIV-exposed infants were colonized more frequently than HIV-unexposed infants (risk ratio, RR: 1.4; 95% confidence interval, CI: 1.0-1.9, P = 0.04). Co-trimoxazole prophylaxis reduced colonization by ca 7% but increased the risk of colonization with co-trimoxazole-resistant pneumococci within 6 weeks of starting prophylaxis (RR: 3.2; 95% CI: 1.3-7.8, P = 0.04). Prophylaxis with co-trimoxazole led to a small but statistically significant increase of nasopharyngeal colonization with pneumococci not susceptible to clindamycin (RR: 1.6; 95% CI: 1.0-2.6, P = 0.04) but did not increase the risk of non-susceptibility to penicillin (RR: 1.1; 95% CI: 0.7-1.7), erythromycin (RR: 1.0; 95% CI: 0.6-1.7), tetracycline (RR: 0.9; 95% CI: 0.6-1.5) or chloramphenicol (RR: 0.8; 95% CI: 0.3-2.3). Co-trimoxazole prophylaxis did not cause the prevailing pneumococcal serotypes to differ from those that are targeted by the 7-valent conjugate pneumococcal vaccine (RR: 1.0; 95% CI: 0.7-1.6). CONCLUSION: Co-trimoxazole prophylaxis modestly suppresses pneumococcal colonization but accelerates infant acquisition of co-trimoxazole- and clindamycin-resistant pneumococci. Co-trimoxazole prophylaxis appears unlikely to compromise the future efficacy of conjugate vaccines.
OBJECTIVE: To ascertain the microbiological consequences of WHO's recommendation for presumptive co-trimoxazole prophylaxis for infants with perinatal HIV exposure. METHODS: Using a longitudinal cohort design, we followed HIV-exposed and HIV-unexposed infants trimonthly for up to 18 months per infant. HIV-exposed infants received daily co-trimoxazole prophylaxis from 6 weeks to > or = 12 months of age. Using Streptococcus pneumoniae as our sentinel pathogen, we measured how co-trimoxazole altered nasopharyngeal colonization, pneumococcal resistance to antibiotics and serotype distribution as a function of co-trimoxazole exposure. FINDINGS: From 260 infants followed for 3096 patient-months, we detected pneumococci in 360/1394 (25.8%) samples. HIV-exposed infants were colonized more frequently than HIV-unexposed infants (risk ratio, RR: 1.4; 95% confidence interval, CI: 1.0-1.9, P = 0.04). Co-trimoxazole prophylaxis reduced colonization by ca 7% but increased the risk of colonization with co-trimoxazole-resistant pneumococci within 6 weeks of starting prophylaxis (RR: 3.2; 95% CI: 1.3-7.8, P = 0.04). Prophylaxis with co-trimoxazole led to a small but statistically significant increase of nasopharyngeal colonization with pneumococci not susceptible to clindamycin (RR: 1.6; 95% CI: 1.0-2.6, P = 0.04) but did not increase the risk of non-susceptibility to penicillin (RR: 1.1; 95% CI: 0.7-1.7), erythromycin (RR: 1.0; 95% CI: 0.6-1.7), tetracycline (RR: 0.9; 95% CI: 0.6-1.5) or chloramphenicol (RR: 0.8; 95% CI: 0.3-2.3). Co-trimoxazole prophylaxis did not cause the prevailing pneumococcal serotypes to differ from those that are targeted by the 7-valent conjugate pneumococcal vaccine (RR: 1.0; 95% CI: 0.7-1.6). CONCLUSION:Co-trimoxazole prophylaxis modestly suppresses pneumococcal colonization but accelerates infant acquisition of co-trimoxazole- and clindamycin-resistant pneumococci. Co-trimoxazole prophylaxis appears unlikely to compromise the future efficacy of conjugate vaccines.
Authors: H J Zar; D Hanslo; E Tannenbaum; M Klein; A Argent; B Eley; J Burgess; K Magnus; E D Bateman; G Hussey Journal: Acta Paediatr Date: 2001-02 Impact factor: 2.299
Authors: D R Feikin; S F Dowell; O C Nwanyanwu; K P Klugman; P N Kazembe; L M Barat; C Graf; P B Bloland; C Ziba; R E Huebner; B Schwartz Journal: J Infect Dis Date: 2000-04-13 Impact factor: 5.226
Authors: Karen M Puopolo; David C Klinzing; Michelle P Lin; Derek L Yesucevitz; Michael J Cieslewicz Journal: J Med Microbiol Date: 2007-07 Impact factor: 2.472
Authors: Anna Dow; Dumbani Kayira; Michael Hudgens; Annelies Van Rie; Caroline C King; Sascha Ellington; Athena Kourtis; Abigail Norris Turner; Steven Meshnick; Zebrone Kacheche; Denise J Jamieson; Charles Chasela; Charles van der Horst Journal: Pediatr Infect Dis J Date: 2012-08 Impact factor: 2.129
Authors: Darlington M Mwenya; Bambos M Charalambous; Patrick P J Phillips; James C L Mwansa; Sarah L Batt; Andrew J Nunn; Sarah Walker; Diana M Gibb; Stephen H Gillespie Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191
Authors: Shabir A Madhi; Alane Izu; Marta C Nunes; Avye Violari; Mark F Cotton; Patrick Jean-Philippe; Keith P Klugman; Anne von Gottberg; Nadia van Niekerk; Peter V Adrian Journal: Vaccine Date: 2015-04-21 Impact factor: 3.641
Authors: Athena P Kourtis; Jeffrey Wiener; Dumbani Kayira; Charles Chasela; Sascha R Ellington; Lisa Hyde; Mina Hosseinipour; Charles van der Horst; Denise J Jamieson Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: Marta C Nunes; Anne von Gottberg; Linda de Gouveia; Cheryl Cohen; Locadiah Kuwanda; Alan S Karstaedt; Keith P Klugman; Shabir A Madhi Journal: PLoS One Date: 2011-11-28 Impact factor: 3.240
Authors: Paul Turner; Claudia Turner; Auscharee Jankhot; Naw Helen; Sue J Lee; Nicholas P Day; Nicholas J White; Francois Nosten; David Goldblatt Journal: PLoS One Date: 2012-05-31 Impact factor: 3.240
Authors: Amy S Labar; Jennifer S Millman; Ellen Ruebush; Japheth A Opintan; Rima A Bishar; A Oladipo Aboderin; Mercy J Newman; Adebayo Lamikanra; Iruka N Okeke Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240